Breast cancer experts are hailing what could be some of the biggest advances in more than a decade – two new medicines that significantly delay the time until women with very advanced cases get worse.

DRUGMAKERS GlaxoSmithKline and Eli Lilly posted weaker than expected quarterly revenue, continuing an industry theme and underscoring challenges from price cuts and a lack of new products.